Core Viewpoint - Adma Biologics has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Adma Biologics indicate an improvement in the company's underlying business, suggesting potential for stock price appreciation [5][8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - Adma Biologics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Adma Biologics is expected to earn $0.58 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 1.6% over the past three months [8].

Core Viewpoint - Adma Biologics reported quarterly earnings of $0.16 per share, matching the Zacks Consensus Estimate, and showing a year-over-year increase from $0.15 per share [1] Financial Performance - The company posted revenues of $134.22 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.17%, and up from $119.84 million a year ago [2] - Over the last four quarters, Adma Biologics has surpassed consensus revenue estimates three times [2] Stock Performance - Adma Biologics shares have declined approximately 14.7% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $139.8 million, and for the current fiscal year, it is $0.57 on revenues of $506.7 million [7] - The trend of earnings estimate revisions for Adma Biologics was mixed prior to the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Group 1 - Adma Biologics closed at $23.52, with a +1.07% change, underperforming the S&P 500's daily gain of 1.47% [1] - Over the past month, shares of Adma Biologics gained 19.64%, outperforming the Medical sector's loss of 2.95% and the S&P 500's loss of 0.47% [1] Group 2 - The upcoming earnings release on May 7, 2025, is expected to show an EPS of $0.16, a 100% increase from the same quarter last year, with projected net sales of $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of $0.71 per share and revenue of $495.8 million, reflecting changes of +44.9% and +16.26% respectively from the previous year [3] Group 3 - Changes in analyst estimates for Adma Biologics are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that Adma Biologics currently holds a Zacks Rank of 2 (Buy) [6] Group 4 - Adma Biologics has a Forward P/E ratio of 32.78, which is a premium compared to the industry average Forward P/E of 17.32 [7] - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7]

Core Viewpoint - Adma Biologics has shown strong stock performance recently, with a +17.7% return over the past month, contrasting with the S&P 500's -0.7% change, indicating potential investor interest and market momentum [2]. Earnings Estimate Revisions - The consensus earnings estimate for Adma Biologics is $0.16 per share for the current quarter, reflecting a year-over-year increase of +100% [5]. - For the current fiscal year, the consensus earnings estimate stands at $0.71, indicating a year-over-year change of +44.9% [5]. - The next fiscal year's consensus earnings estimate is $0.93, representing a +31% change from the previous year [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), suggesting a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, indicating a year-over-year increase of +45.5% [11]. - For the current fiscal year, the sales estimate is $495.8 million, reflecting a +16.3% change, while the next fiscal year's estimate is $611.5 million, indicating a +23.3% change [11]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics generated revenues of $117.55 million, a year-over-year increase of +59.1% [12]. - The EPS for the same period was $0.14, compared to $0.04 a year ago, with a revenue surprise of +4.77% against the Zacks Consensus Estimate [12]. - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped revenue estimates each time [13]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [17].

Company Overview - Adma Biologics (ADMA) shares increased by 7.8% to close at $20.91, driven by notable trading volume and broader market optimism [1] - The stock has gained 5.3% over the past four weeks, indicating strong fundamentals [1] Earnings Expectations - Adma Biologics is expected to report quarterly earnings of $0.16 per share, reflecting a year-over-year increase of 100% [2] - Revenue projections stand at $119.1 million, which is a 45.5% increase compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Adma Biologics has remained unchanged over the last 30 days, suggesting that the stock's price movement may not sustain without earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 2 (Buy), indicating positive market sentiment [3] Industry Comparison - Adma Biologics operates within the Zacks Medical - Biomedical and Genetics industry, where Blueprint Medicines (BPMC) has seen a 2.1% increase to $82.53, but has returned -9.8% over the past month [3] - Blueprint Medicines has a consensus EPS estimate of -$0.41, which is a 15.4% change over the past month and a 68.9% change from the previous year [4]